Lyra Therapeutics Inc
NASDAQ:LYRA

Watchlist Manager
Lyra Therapeutics Inc Logo
Lyra Therapeutics Inc
NASDAQ:LYRA
Watchlist
Price: 3.36 USD -0.59% Market Closed
Market Cap: 5.9m USD

Operating Margin
Lyra Therapeutics Inc

-5 401.3%
Current
-4 350%
Average
6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-5 401.3%
=
Operating Profit
-32.4m
/
Revenue
600k

Operating Margin Across Competitors

No Stocks Found

Lyra Therapeutics Inc
Glance View

Market Cap
5.5m USD
Industry
Pharmaceuticals

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. The company is headquartered in Watertown, Massachusetts and currently employs 53 full-time employees. The company went IPO on 2020-05-01. The firm is focused on development and commercialization of novel drug and delivery solutions for the treatment of patients with ear, nose, and throat (ENT) diseases. Its technology platform, XTreo, is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210 and LYR-220, are bioresorbable polymeric matrices administered in a non-invasive, in-office procedure to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (CRS). LYR-210 is an anti-inflammatory implantable drug matrix based on its XTreo platform that is designed to elute mometasone furoate (MF) to the inflamed mucosal tissue for up to six months in surgically naive CRS patients. LYR-220 is an investigative therapy for CRS patients with and without nasal polyps.

LYRA Intrinsic Value
15.97 USD
Undervaluation 79%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-5 401.3%
=
Operating Profit
-32.4m
/
Revenue
600k
What is the Operating Margin of Lyra Therapeutics Inc?

Based on Lyra Therapeutics Inc's most recent financial statements, the company has Operating Margin of -5 401.3%.

Back to Top